Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech medical breakthrough

NUS PEMF Magnetic Pulses Reprogram Immune Cells Against Breast Cancer

Analysis based on 10 articles · First reported Sep 13, 2026 · Last updated Sep 15, 2026

Sentiment
15
Attention
2
Articles
10
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

This breakthrough could positively impact the biotechnology and pharmaceutical sectors by offering a non-invasive, drug-free alternative for breast cancer treatment, potentially reducing reliance on chemotherapy and its side effects. However, commercial impact remains years away pending Phase 2 trials and regulatory approvals from agencies such as the Singapore Singapore — Health Sciences Authority and the US United States — Food and Drug Administration.

biotechnology pharmaceuticals healthcare

Researchers at the National University of Singapore (NUS) have demonstrated a non-invasive approach for targeted breast cancer therapy using pulsed electromagnetic fields (PEMFs). The study, led by Associate Professor Alfredo Franco-Obregon from the NUS Yong Loo Lin School of Medicine and the NUS Institute for Health Innovation & Technology, was published in the journal Smart Medicine on 4 June 2026. The team successfully reprogrammed tumour-associated macrophages (TAMs), immune cells that typically promote cancer growth, into an active anti-tumour state that attacks and destroys cancer cells. In preclinical models, PEMF treatment completely eradicated tumours in 75 per cent of tested models after just four 30-minute sessions, without chemotherapy. The key mechanism involves the TRPC1 protein, which acts as a molecular switch; a brief 10-minute PEMF exposure activated TRPC1 channels on M2-like TAMs, converting them to the M1 state. The same PEMF device has completed Phase 1 clinical trials demonstrating safety in humans, and the team is now seeking partners for Phase 2 efficacy trials. The research builds on earlier work showing that PEMF exposure enhances uptake of the chemotherapy drug doxorubicin by breast cancer cells, potentially halving the effective dosage needed. The team is optimistic the therapy could be a complementary treatment for other cancers beyond breast cancer. Breast cancer cases are projected to rise by a third, from 2.3 million in 2023 to more than 3.5 million by 2050, underscoring the urgent need for innovative therapies.

per
Associate Professor Alfredo Franco-Obregon led the research team and is the key spokesperson for the study. His leadership and expertise are central to the development of the PEMF therapy.
Importance 90.0 Sentiment 15.0
cnt
Singapore is the home country of the research and stands to benefit from advancements in its biomedical sector. The study reinforces Singapore's position as a hub for medical innovation.
Importance 50.0 Sentiment 10.0
oth
Smart Medicine is the peer-reviewed journal that published the study, lending scientific credibility to the findings. The publication raises the journal's profile in oncology research.
Importance 40.0 Sentiment 5.0
oth
Doxorubicin is a chemotherapy drug whose uptake is enhanced by PEMF exposure, potentially allowing lower dosages and reduced side effects. The research may affect demand for doxorubicin if PEMF therapy reduces required chemotherapy doses.
Importance 30.0 Sentiment 0.0
govactor
The Singapore Singapore — Health Sciences Authority is a regulatory body that would need to approve the PEMF therapy for clinical use in Singapore. Its future decisions will be critical for market access.
Importance 20.0 Sentiment 0.0
govactor
The US United States — Food and Drug Administration is a key regulatory agency for approval of the PEMF therapy in the United States. Its approval would open a large market for the treatment.
Importance 20.0 Sentiment 0.0
cnt
The United States is a potential major market for the PEMF therapy, pending FDA approval. The research could lead to future clinical trials and commercialization in the US.
Importance 15.0 Sentiment 0.0
cnt
Indonesia is mentioned as a nearby country that may watch the development of this therapy, with potential future access to the treatment. The impact is currently minimal but could grow with successful trials.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.